Expert Interview
Evaluating Atacicept in the Treatment of Immunoglobulin A Nephropathy (IgAN): Insights from Vera Therapeutics' Phase 2b ORIGIN Study
Ticker(s): VERAInstitution: USC
- Associate Professor of Medicine at Keck-USC School of Medicine & Medical Director of the CKD program and the Renal, Hypertension and Transplant Clinic at the LAC+USC.
- Treats patients with both HRS1 and HRS2 and over 200 patients with Anemia-CKD.
- Research focuses on advancing kidney dialysis, liver dialysis and providing a support system for the MOF/MODS multisystem failures; has been actively conducting major pharmaceutical sponsored phase II-IV clinical trials in hypertension, anemia, iron, and secondary hyperparathyroidism.
Could you please explain the mechanism of action of atacicept and how it differentiates from other treatments available for IgAN, especially considering its dual inhibition of BAFF and APRIL?
Added By: catalin_adminBased on the week 36 data from the Phase 2b ORIGIN study, how does atacicept's efficacy compare to other IgAN treatments? Are there specific outcomes, like the substantial reduction in serum Gd-IgA1 and resolution of hematuria, that stand out in its effectiveness?
Added By: catalin_adminGiven that atacicept aims to target the source of IgAN through its unique mechanism, how does it address the unmet medical needs in IgAN therapy?
Added By: catalin_adminThe initial data indicates a significant reduction in serum Gd-IgA1 levels. How significant are these findings, and what implications might they have for the broader IgAN patient population?
With the ongoing Phase 3 ORIGIN trial and expected data from the open-label extension in the first half of 2024, what are your expectations for the global reception and potential adoption of atacicept?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
